featured
Comparing Cardiovascular Safety of Linagliptin With Other Glucose-Lowering Agents Using Claims Databases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diabetes, Obesity & Metabolism
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Cardiovascular Safety of Linagliptin Compared With Other Oral Glucose-Lowering Agents in Patients With Type 2 Diabetes: A Sequential Monitoring Programme in Routine Care
Diabetes Obes Metab 2019 Aug 01;21(8)1824-1836, E Patorno, C Gopalakrishnan, KG Brodovicz, A Meyers, DB Bartels, J Liu, M Kulldorff, S SchneeweissFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.